rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Shows Protective Effects in Mouse Models of Parkinson's Disease

RPEP-005581999Sikiric, P; Marovic, A; Matoz, W; Anic, T; Buljat, G; Mikus, D; Stancic-Rokotov, D; Separovic, J; Seiwerth, S; Grabarevic, Z; Rucman, R; Petek, M; Ziger, T; Sebecic, B; Zoricic, I; Turkovic, B; Aralica, G; Perovic, D; Duplancic, B; Lovric-Bencic, M; Rotkvic, I; Mise, S; Jagic, V; Hahn, V
Animal StudyPreliminary evidence
The takeaway

BPC-157 reduced Parkinson's-like symptoms caused by MPTP and haloperidol in mice while simultaneously protecting their stomachs from damage caused by these same drugs.

Dual protection

BPC-157 protected both the brain (reducing PD symptoms) and gut (preventing gastric lesions) from parkinsongenic agents simultaneously

What the researchers found

BPC-157 attenuated both MPTP- and haloperidol-induced Parkinson's-like symptoms in mice while simultaneously protecting against gastric lesions caused by these parkinsongenic agents.

Why it matters

Parkinson's disease has limited treatment options. A peptide that reduces dopaminergic neuronal damage while protecting the gut (which is also affected in Parkinson's) addresses two aspects of this disease simultaneously.

How the study worked

Animal study in mice using two Parkinson's models: MPTP (30 mg/kg daily for 4 days) and haloperidol. BPC-157 at microgram and nanogram doses was tested for behavioral (motor) and gastroprotective effects.

What this study cannot tell us

Mouse models don't fully replicate human Parkinson's. MPTP and haloperidol models represent acute dopamine disruption, not chronic neurodegeneration. No direct measurement of dopamine neuron survival.

How to read the evidence

Preliminary animal evidence from two complementary Parkinson's models showing consistent neuroprotective and gastroprotective effects.

When this study was published

Published in 1999. BPC-157's dopaminergic and neuroprotective effects have been studied further, with the gut-brain axis becoming a major focus in Parkinson's research.

The bigger picture

Parkinson's disease involves both brain and gut pathology. BPC-157's dual neuroprotective and gastroprotective effects align with the emerging understanding of Parkinson's as a gut-brain disorder.

Questions still open

  • Does BPC-157 protect dopamine neurons directly or modulate downstream signaling?
  • Could BPC-157 slow Parkinson's progression in chronic models?
  • Is BPC-157's neuroprotection related to its gut-brain axis effects?

Common questions

Could BPC-157 help Parkinson's disease?
In mice, BPC-157 reduced Parkinson's symptoms from two different causes. This is early animal evidence, but it suggests BPC-157 may protect dopamine neurons. Human studies would be needed to confirm any benefit.
Why does a gut peptide affect Parkinson's?
Parkinson's disease is increasingly understood as a gut-brain disorder — it may actually start in the gut. A gastric peptide that affects the dopamine system and protects both gut and brain is uniquely positioned for this disease.

Read the original research

A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.

Journal of physiology, Paris, 93(6), 505-12

View on PubMed ↗

Citation

Sikiric, P; Marovic, A; Matoz, W; Anic, T; Buljat, G; Mikus, D; Stancic-Rokotov, D; Separovic, J; Seiwerth, S; Grabarevic, Z; Rucman, R; Petek, M; Ziger, T; Sebecic, B; Zoricic, I; Turkovic, B; Aralica, G; Perovic, D; Duplancic, B; Lovric-Bencic, M; Rotkvic, I; Mise, S; Jagic, V; Hahn, V. (1999). A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.. Journal of physiology, Paris, 93(6), 505-12.